Italy has joined a growing list of countries suspected of Chinese-made COVID-19 vaccines.
Italian Prime Minister Mario Draghi told reporters at the end of the EU summit on June 22 that “China’s vaccine … shows that it is not enough. You can see from Chile’s experience in tackling the epidemic.”
More than half of Chile’s population has received the China-made Sinovac vaccine, but the reported efficacy rate is 16 percent after the first dose and 67 percent after the second. 19 the most
On June 24, Feng Zijian, a researcher and former deputy director of the China Centers for Disease Control and Prevention. He admitted in an interview with Chinese state media CCTV that Chinese-made vaccines do not produce enough antibodies and are less effective against them. The Delta variant—formerly known as the Indian variant—of the virus.
Delta variants account for 85 percent of infections in the latest phase of COVID-19. in Guangdong Province of China Although tens of millions of local people have been vaccinated.
The Chinese vaccine is not yet approved for use in the United States or the European Union. Chinese vaccines are not included in the EU’s digital vaccination program. The Chinese government has announced countermeasures. It does not allow unvaccinated tourists from China to enter the country. And vaccination with non-Chinese vaccines is unknown. The measure has prevented many overseas Chinese from returning to the country.
Despite the low efficiency and lack of transparency in the experimental data The World Health Organization recently approved both Sinopharm and Sinovac vaccines for emergency use.
The decision comes as many countries around the world are raising doubts about China’s vaccine.
On June 17, more than 350 doctors and health workers in Indonesia were infected with COVID-19. Even after receiving the Chinovak vaccine Dozens of patients were hospitalized. This raises serious doubts about the vaccine’s effectiveness. especially with other virus strains. Indonesia has bought and administered large quantities of Chinese vaccines to its citizens.
The United Arab Emirates released the Sinopharm vaccine to the general public in December 2020 and has offered the third dose of Sinopharm since March. After it was discovered that the vaccine did not produce enough antibodies for some recipients.
In March, Gao Fu, director of the China Centers for Disease Control and Prevention, said a vaccination for COVID-19 may be necessary. Made in China, the third volume to increase efficiency.
in April At the China National Conference on Vaccines and Health Gao acknowledged that the Chinese vaccine, which uses inactivated viruses Provides low protection against infection And vaccine efficacy could be improved with different types of vaccine combinations. produced with different technologies, such as the mRNA used by Western vaccines.
that same month The United Arab Emirates has begun offering a Pfizer/BioEntech vaccine to encourage Chinese vaccinations.
at the beginning of June 47 percent of Bahrain’s population is fully vaccinated, with 60 percent receiving Sinopharm vaccination. However, the number of confirmed cases is now a record high in Bahrain. and since the end of May Authorities have now offered the Pfizer vaccine as a booster for people who have been fully vaccinated with Sinopharm.
in early June A clinical study in Serbia reported that 30 percent of people aged 65 and over did not produce antibodies after receiving the sinofam vaccine. Serbia is the first country in Europe to use a Chinese vaccine. Although it is not approved by the European Medicines Agency.
Several countries in Latin America, Africa and Asia, including Hungary and Serbia in Europe, are administering Chinese vaccines. There is an increasing number of COVID-19 infections.
According to Our World in Data, countries such as Seychelles, Chile, Bahrain and Mongolia, which account for about 50 to 68% of the total vaccinated population from China, are among the top 10 with the most severe COVID-19 outbreaks.